Societal CDMO Liabilities 2024

Societal CDMO Aktienanalyse

What does Societal CDMO do?

Recro Pharma Inc. is a company operating in the biopharmaceutical industry, specializing in the development and marketing of innovative therapeutics. The company is based in Malvern, Pennsylvania, USA, and was founded in 2007. The history of Recro Pharma Inc. dates back to 1985, when the company was founded as ReceptoPharm. In 2008, it was renamed Recro Pharma Inc. to emphasize its focus on pharmaceutical activities. Since then, the company has made significant progress, including successful clinical trials and the introduction of innovative products. Recro Pharma follows a business model based on the development of therapeutics in the areas of pain management and anesthesia. The company aims to create solutions to alleviate pain in patients and improve their quality of life. Recro Pharma's goal is to bring high-quality products to the market that are distinguished by excellent safety, efficacy, and patient tolerance. Recro Pharma's product range currently includes two main areas. Firstly, the company has launched its medication Meloxicam for pain treatment in adults. Secondly, it has developed and distributes a portfolio of anesthesia-related therapeutics through its subsidiary Lumendi LLC. Meloxicam is a non-steroidal anti-inflammatory drug used for pain relief in adults. The medication is available in various forms such as tablets and capsules and is used in both hospital and outpatient care. Lumendi LLC specializes in the development and distribution of anesthesia-related therapeutics. The company's products include those for intubation and muscle relaxation in surgical procedures, as well as anesthesia for pain management. Lumendi's goal is to create innovative solutions to improve medical practice and shorten hospital stays. Recro Pharma Inc. aims to expand its product range through the development of further innovative solutions. The company continues to invest in research and development to develop new products and strengthen its position in the market. In 2020, Recro Pharma Inc. received FDA approval for the product IV Meloxicam. This is an intravenous form of the drug Meloxicam used for pain treatment in adults. This is a significant milestone for the company as it is now able to offer an alternative form of the medication. Recro Pharma Inc. has established itself as a significant player in the biopharmaceutical industry. The company aspires to further strengthen its position in the market and create innovative solutions to improve medical practice. With its high-quality products, Recro Pharma contributes to alleviating patients' pain and improving their quality of life. Societal CDMO ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Societal CDMO's Liabilities

Societal CDMO's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Societal CDMO's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Societal CDMO's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Societal CDMO's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Societal CDMO’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Societal CDMO stock

What is the level of liabilities of Societal CDMO this year?

Societal CDMO has a debt balance of 94.81 M USD this year.

What were the liabilities of Societal CDMO compared to the previous year?

The liabilities of Societal CDMO have increased by -2.86% dropped compared to the previous year.

What are the consequences of high debt for investors of Societal CDMO?

High liabilities can pose a risk for investors of Societal CDMO, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Societal CDMO?

Low liabilities mean that Societal CDMO has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Societal CDMO affect the company?

An increase in liabilities of Societal CDMO can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Societal CDMO affect the company?

A decrease in the liabilities of Societal CDMO can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Societal CDMO?

Some factors that can influence the liabilities of Societal CDMO include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Societal CDMO so important for investors?

The liabilities of Societal CDMO are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Societal CDMO take to modify the liabilities?

To change its liabilities, Societal CDMO can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Societal CDMO pay?

Over the past 12 months, Societal CDMO paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Societal CDMO is expected to pay a dividend of 0 USD.

What is the dividend yield of Societal CDMO?

The current dividend yield of Societal CDMO is .

When does Societal CDMO pay dividends?

Societal CDMO pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Societal CDMO?

Societal CDMO paid dividends every year for the past 0 years.

What is the dividend of Societal CDMO?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Societal CDMO located?

Societal CDMO is assigned to the 'Health' sector.

Wann musste ich die Aktien von Societal CDMO kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Societal CDMO from 10/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/24/2024.

When did Societal CDMO pay the last dividend?

The last dividend was paid out on 10/24/2024.

What was the dividend of Societal CDMO in the year 2023?

In the year 2023, Societal CDMO distributed 0 USD as dividends.

In which currency does Societal CDMO pay out the dividend?

The dividends of Societal CDMO are distributed in USD.